SPARC and glioma: Therefore, to determine whether SPARC expression or siRNA inhibition of HSP27 or AKTs enhanced the sensitivity of these PTEN-mutant, p53 wild-type glioma cells to TMZ, we treated the cells for 48 hr when no effects from TMZ alone are observed.